Related Experiment Video
Updated: May 24, 2026

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Hyperactivation of 4E-binding protein 1 as a mediator of biguanide-induced cytotoxicity during glucose deprivation
Junichi Matsuo1, Yoshinori Tsukumo, Sakae Saito
1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Abstract:
Biguanides, including metformin, buformin, and phenformin, are potential antitumorigenic agents and induce cell death during glucose deprivation, a cell condition that occurs in the tumor microenvironment. Here, we show that this selective killing of glucose-deprived cells is coupled with hyperactivation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), a negative regulator of translation initiation. We found, in fact, that the 4E-BP1 hyperactivation led to failure of the unfolded protein response (UPR), an endoplasmic reticulum-originated stress signaling pathway for cell survival. We also found that the 4E-BP1-mediated UPR inhibition occurred through a strong inhibition of the mTOR signaling pathway, a proven antitumor target. Importantly, the 4E-BP1 hyperactivation can be also seen in xenografted cancer cells through an in vivo biguanide treatment. Our findings indicate that antitumor action of biguanides can be mediated by 4E-BP1 hyperactivation, which results in UPR inhibition and selective cell killing when glucose is withdrawn.
Insights
Biguanides like metformin selectively kill glucose-deprived cancer cells by hyperactivating eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), inhibiting cell survival pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Stress Response
Background:
- Biguanides (metformin, buformin, phenformin) show potential as antitumor agents.
- These drugs induce cell death under glucose deprivation, a condition prevalent in tumors.
- Glucose deprivation is a critical factor in the tumor microenvironment influencing treatment efficacy.
Purpose of the Study:
- To elucidate the molecular mechanisms by which biguanides induce cell death in glucose-deprived cancer cells.
- To investigate the role of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) in biguanide-mediated cell death.
- To explore the connection between 4E-BP1, the unfolded protein response (UPR), and the mTOR signaling pathway in cancer therapy.
Main Methods:
- Cellular assays to assess biguanide effects on glucose-deprived cells.
- Western blotting and molecular analysis to evaluate protein activation and signaling pathways (4E-BP1, UPR, mTOR).
- In vivo studies using xenografted cancer models treated with biguanides.
Main Results:
- Biguanide treatment leads to hyperactivation of 4E-binding protein 1 (4E-BP1) in glucose-deprived cells.
- Hyperactivated 4E-BP1 inhibits the unfolded protein response (UPR), a key cell survival pathway.
- This inhibition of UPR is mediated by the suppression of the mTOR signaling pathway.
- Biguanide-induced 4E-BP1 hyperactivation and subsequent UPR inhibition were confirmed in vivo.
Conclusions:
- Antitumor effects of biguanides are linked to 4E-BP1 hyperactivation.
- This mechanism selectively eliminates glucose-deprived cancer cells by disrupting UPR.
- Targeting the 4E-BP1/UPR/mTOR axis offers a potential therapeutic strategy for cancers experiencing glucose deprivation.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hyperglycemia
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Dipeptidyl Peptidase 4 Inhibitors
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Cell Specific Gene Expression
